New survey highlights persistent cancer medication shortages across United States

The National Comprehensive Cancer Network (NCCN) released new data on generic cancer drug shortages in the United States, drawing on responses from pharmacy directors and other clinical and administrative leaders at its member institutions. The survey, conducted in late August, captured the experiences of cancer centers across the country regarding the availability of anticancer agents.

According to the findings, every responding center reported a shortage of at least one anticancer medication. In addition, more than one‑fifth of the institutions indicated that they were concurrently facing shortages of five or more different drugs. The data highlight a widespread and escalating challenge in the supply of essential cancer therapies, underscoring the need for coordinated efforts to address these gaps.

These results underscore the urgency for stakeholders—pharmaceutical manufacturers, regulators, and health‑care providers—to collaborate on strategies that secure a stable supply of generic cancer medications and mitigate the impact on patient care.